LON:OPTI

OptiBiotix Health Final Earnings Results & Report

OptiBiotix Health logo
GBX 4.40 -0.15 (-3.30%)
As of 11:57 AM Eastern

OptiBiotix Health reported Final earnings on May 28, 2026. The company reported EPS of -GBX 3.84, while revenue was £1.17 million.

Earnings Announcement Details

Quarter
Final
Report Date
Time
Before Market Opens

OptiBiotix Health EPS Results

Actual EPS
-GBX 3.84
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

OptiBiotix Health Revenue Results

Actual Revenue
£1.17 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

OptiBiotix Health Final Earnings FAQ

OptiBiotix Health (LON:OPTI) reported earnings of -GBX 3.84 per share for Final. The report was announced on Thursday, May 28, 2026.

OptiBiotix Health reported revenue of £1.17 million for Final.

OptiBiotix Health Earnings Headlines

OptiBiotix Health Plc H1 Loss Rises
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
See More OptiBiotix Health Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like OptiBiotix Health? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OptiBiotix Health and other key companies, straight to your email.

About OptiBiotix Health

OptiBiotix Health (LON:OPTI) (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness. OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks. OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

View OptiBiotix Health Profile